Cytopia’s development programs in targeted therapeutics have lead to a diverse pipeline of drug compounds ranging from early stage leads to qualified drug candidates. The kinase inhibitors in this maturing pipeline focus on cancer, but also address diseases in areas as diverse as cardiovascular and immunology. Cytopia's cancer programs are being developed internally with some opportunities best addressed through clinical stage development while others need partners to fully exploit their market and therapeutic potential.
Please contact Mr. Andrew Macdonald, Chief Executive Officer for further information on collaborations or licensing opportunities.
